{"database": "lobbying", "table": "lobbying_activities", "rows": [[1984555, "fac8943f-589a-4fb2-b2cf-f3e2c2750568", "Q2", "RED+BLUE STRATEGIES", 400693064, "PEW CHARITABLE TRUSTS", 2017, "second_quarter", "PHA", "S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. \n\nH.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. \n\nS. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. \n\nH.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. \n\nIssues related to antibiotic innovation and advancement.\n\nIssues related opioid abuse and methods to fight against the opioid epidemic in the United States.\n\nIssues related to ensuring the safety of compounded medications. \n\nIssues related to over the counter medications and supplements. \n\nIssues related to the Physician Payment Sunshine Act and the Open Payments system.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2017-07-10T14:44:54.160000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1984555"], "units": {}, "query_ms": 10.379257961176336, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}